

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. **(Withdrawn)** A pharmaceutical composition comprising (i) a polynucleotide encoding an HIV envelope protein and (ii) a polynucleotide encoding a CD4 receptor.
2. **(Withdrawn)** A pharmaceutical composition according to claim 1 wherein (i) are (ii) are encoded on separate vectors.
3. **(Withdrawn)** A pharmaceutical composition according to claim 1 wherein (i) and (ii) are encoded on the same vector.
4. **(Withdrawn)** A pharmaceutical composition according to claim 1 wherein said HIV envelope protein and said CD4 receptor are expressed as separate proteins.
5. **(Withdrawn)** A pharmaceutical composition comprising (i) a polynucleotide encoding an HIV envelope protein and (ii) a CD4 receptor.
6. **(Withdrawn)** A pharmaceutical composition according to claim 1 wherein the HIV envelope protein is expressed as part of a fusion protein and/or the CD4 receptor is expressed as part of a fusion protein.
7. **(Withdrawn)** A pharmaceutical composition according to claim 1 wherein the CD4 receptor is soluble CD4 receptor.
8. **(Withdrawn)** A pharmaceutical composition according to claim 1 wherein the CD4 receptor is human CD4 receptor.
9. **(Withdrawn)** A pharmaceutical composition according to claim 1 wherein the CD4 receptor is a CD4 surrogate molecule.
10. **(Withdrawn)** A pharmaceutical composition according to claim 1 wherein the CD4 receptor is a CD4 surrogate molecule which is M33 mini-protein.

11. **(Withdrawn)** A pharmaceutical composition according to claim 1 wherein the HIV envelope protein is HIV-1 envelope protein.
12. **(Withdrawn)** A pharmaceutical composition according to claim 1 wherein the HIV envelope protein is CCR5-dependent HIV envelope protein.
13. **(Withdrawn)** A pharmaceutical composition according to claim 1 wherein the polynucleotide encoding the HIV envelope protein encodes gpl60.
14. **(Withdrawn)** A pharmaceutical composition according to claim 1 further comprising a pharmaceutically acceptable diluent or excipient.
15. **(Withdrawn)** A pharmaceutical composition according to claim 1 for use in the treatment of HIV.
16. **(Withdrawn)** A pharmaceutical composition according to claim 1 in the form of a vaccine.
17. **(Withdrawn)** A method of treating or preventing HIV infection which method comprises administering to a subject a pharmaceutical composition as defined in claim 1.
18. **(Withdrawn)** A fixed cell wherein said cell expresses an HIV envelope protein and further wherein said envelope protein is complexed with a CD4 receptor.
19. **(Withdrawn)** A method of treating or preventing HIV infection which method comprises administering to a subject a fixed cell as defined in claim 18.
20. **(Withdrawn)** A method of treating or preventing a disease or condition of, or related to, the immune system which method comprises administering to a fixed cell as defined in claim 18.
21. **(Withdrawn)** A vaccine comprising the fixed cell as defined in claim 20.
22. **(Withdrawn)** Use of a fixed cell as defined in claim 20 for the preparation of a

medicament for use in generating anti-HIV monoclonal antibodies.

23. **(Currently Amended)** An isolated or synthesized antibody immunospecific for ~~the~~ a fixed cell comprising an HIV envelope complex encoded by gp 160 and further wherein said envelope is complexed with a CD4 receptor ~~as defined in claim 20.~~

24. **(Previously Presented)** A method of treating or preventing HIV infection which method comprises administering to a subject an antibody as defined in claim 23.

25. **(Previously Presented)** A method of treating or preventing a disease or condition of, or related to, the immune system which method comprises administering to a subject an antibody as defined in claim 23.

26. **(Currently Amended)** A hybridoma cell line having the identifying characteristics of the cell line deposited with the Advanced Biotechnology Center Inter Lab Cell Line Collection (CBA ICLB) under Deposit number PD03002 wherein said hybridoma produces DB-81.

27. **(Previously Presented)** An antibody molecule produced by the hybridoma of claim 26.

28. **(Previously Presented)** An antibody that specifically binds the same idiotope as the antibody produced by the hybridoma of claim 26.

29. **(Withdrawn)** A method of generating a fixed cell according to claim 18 comprising
(i) expressing HIV envelope protein on the surface of living cells;
(ii) complexing the envelope protein of(i) with a CD4 receptor; and
(iii) fixing the CD4 coated cells.

30. **(Withdrawn)** A pharmaceutical composition comprising a fixed cell according to claim 23 and a pharmaceutically acceptable diluent or excipient.

31. **(Withdrawn)** A pharmaceutical composition comprising a population of fixed cells according to claim 23, wherein within the population more than one HIV envelope serotype is expressed, and a pharmaceutically acceptable diluent or excipient.